日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Eli Lilly plans to introduce its weight loss drug in China soon

By Zhou Wenting | chinadaily.com.cn | Updated: 2024-12-06 19:24
Share
Share - WeChat
The booth of US pharmaceutical company Eli Lilly and Co at the seventh China International Import Expo held in Shanghai in November 2024. [Photo provided to chinadaily.com.cn]

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its innovative weight loss therapy available to patients in China very soon.

"At Lilly, we're committed to supporting individuals affected by obesity, which is a chronic disease that requires effective treatment options and long-term management," said Huzur Devletsah, president and general manager of Lilly China.

Her comment came after Lilly announced the top-line results from the SURMOUNT-5 clinical trial that day, showing that its Zepbound (tirzepatide) provided a 47 percent greater relative weight loss compared to Wegovy (semaglutide) by Danish pharmaceutical company Novo Nordisk.

Wegovy was marketed earlier than Zepbound, and is currently the world's best-selling GLP-1 weight loss medicine.

Lilly said the trial results showed that on average, Zepbound led to a weight loss of 20.2 percent compared to 13.7 percent with Wegovy. A key competitiveness of Zepbound lies in that it is the only US FDA-approved product that activates both GLP-1 and GIP - two receptors playing key roles in regulating blood sugar and energy balance in the human body.

GLP-1 therapies, originally used to treat type 2 diabetes, have gained popularity throughout the world due to their weight loss effect in recent years. Novo Nordisk and Lilly are currently the main global leaders.

The companies' financial reports showed that in the first three quarters of this year, Wegovy's revenue was about $5.53 billion, a year-on-year increase of 77 percent, and Zepbound's revenue was nearly $3.02 billion after the figure exceeded $1 billion for the first time in the second quarter.

British bank Barclays predicted that the global weight loss therapy market will grow to $150 billion by 2030. And according to the forecast of US consultancy Frost & Sullivan, the market size of GLP-1 medicines in China will exceed 50 billion yuan in 2030.

Domestic medical experts said that such positive trial results may affect doctors' drug recommendations in clinical use, but which therapies to prescribe may be affected by multiple factors, including indications, prices, reimbursement policies, and patient preferences.

In October, Lilly announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, aiming to increase production of such innovative medicines.

During a previous interview with media outlet ThePaper.cn, Zhou Xiaping, global senior vice-president of Novo Nordisk and president of Novo Nordisk China, said that with full confidence in its products, the company welcomes healthy competition in the field of GLP-1 medicines to jointly help more obese patients.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲高清国产拍精品影院 | 一色屋任你操 | 欧美一区黄 | 亚洲成av人片在线观看 | av网址在线播放 | 91精品国产高清久久久久久91 | 亚洲国产成人精品女人久久久 | 日韩国产欧美在线观看 | 亚洲熟妇毛茸茸 | 国产精品久久久久久久久久免费看 | 久久亚洲综合 | 亚洲人一区 | 国产一区二区免费 | 欧美精彩视频在线观看 | 夜夜天堂| 精品极品三级久久久久 | 一区二区三区 日韩 | a级在线观看| 精品久久一二三区 | 99re在线观看 | 999精品视频在线观看 | 亚洲欧美不卡 | 国产精品久久久久久久久久久久 | 伊人狠狠丁香婷婷综合色 | 国产精品国产精品 | 欧美日韩亚洲一区二区 | 91短视频在线免费观看 | 亚洲日本中文字幕永久 | 男女一进一出无遮挡黄 | 精品久久久久久久久久久久久久 | 日韩高清一区 | 亚洲欧美日韩中文字幕在线不卡 | 亚洲www啪成人一区二区麻豆 | 欧美午夜在线 | 免费国产精品视频在线 | 啪啪天堂| 成人伊人| 久久久综合 | 一区二区三区视频免费 | 二区国产| 精品一区二区三区四区五区 |